Discovery, evaluation, prevention, and control of liver injury risk by Polygoni Multiflori Radix

Abstract

In recent years, adverse reactions and events associated with traditional Chinese medicines (TCM) and herbal medicines (HM) have frequently occurred. In particular, with regard to the safety of newly discovered TCM that have been deemed “toxic,” providing a scientifically based answer and developing effective solutions is challenging. Owing to the complexity of TCM/HM products and lack of systematic research, our understanding of the potential causes of TCM/HM-induced liver injury is limited. Therefore, significant advancements in understanding the toxicity of TCM and preventing and managing safety risks are urgently needed to address the safety concerns associated with TCM/HM. Using Polygoni Multiflori Radix (PMR) hepatotoxicity as a typical example, we evaluated the “integrated evidence chain” based on the causality evaluation of TCM-induced liver injury, and confirmed the objective authenticity of PMR hepatotoxicity. Furthermore, we first proposed and established a disease-syndrome-combined toxicology model that was applied to the material basis and analysis of the mechanism of PMR-induced hepatotoxicity. The mechanism hypothesis of “three-factor-induced toxicity” of idiosyncratic hepatotoxicity of TCM was proposed and confirmed. Based on this, the disease characteristics of the population susceptible to PMR idiosyncratic hepatotoxicity were elucidated, and various biomarkers were screened and identified, including the genetic marker HLA-B*35:01 and immunological and metabolomic markers. Finally, the study explored and established a safe medication strategy and method for “host-drug-use” three-dimensional risk prevention and control based on identifying susceptible individuals, controlling susceptible substances, and clinical precision medication. This study provides a foundation for comprehensively understanding the scientific implications of TCM/HM toxic side reactions and establishing scientific and effective risk prevention and control strategies.

Keywords

Causality evaluation / Liver injury / Mechanism / Polygoni Multiflori Radix / Risk prevention and control

References

[[1]] Huang K, Zhang P, Zhang Z, et al. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. Pharmacol Ther. 2021;225:107843.

[[2]] Gong J, Xie J, Bedolla R, et al. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res. 2014;20(5):1259-1273.

[[3]] Lian F, Li G, Chen X, et al. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial. J Clin Endocrinol Metab. 2014;99(2):648-655.

[[4]] Lam WC, Lyu A, Bian Z. ICD-11: impact on traditional Chinese medicine and world healthcare systems. Pharmaceut Med. 2019;33(5):373-377.

[[5]] Lee FY, Wong HS, Chan HK, et al. Hepatic adverse drug reactions in Malaysia: an 18-year review of the national centralized reporting system. Pharmacoepidemiol Drug Saf. 2020;29(12):1669-1679.

[[6]] Yousaf MN, Chaudhary FS, Hodanazari SM, et al. Hepatotoxicity associated with Garcinia cambogia: a case report. World J Hepatol. 2019;11(11):735-742.

[[7]] Brar HS, Marathi R. Case of cholestatic drug-induced liver injury (DILI) associated with black cohosh. BMJ Case Rep. 2021;14(5):e240408.

[[8]] Ferreira GSA, Watanabe ALC, Trevizoli NC, et al. Acute liver failure caused by use of fat burner: a case report. Transplant Proc. 2020;52(5):1409-1412.

[[9]] Xia C, Liu Y, Yao H, et al. Causality assessment of skyfruit-induced liver injury using the updated RUCAM: a case report and review of the literature. J Int Med Res. 2020;48(4):300060520917569.

[[10]] Shao YM, Zhang Y, Yin X, et al. Herb-induced autoimmune-like hepatitis associated with Xiang-tian-guo (Swietenia macrophylla seeds): a case report and literature review. Medicine (Baltim). 2021;100(2):e24045.

[[11]] Tan Y, Chen H, Zhou X, et al. RUCAM-based assessment of liver injury by Xiang-Tian-Guo (Swietenia macrophylla) seeds, a plant used for treatment of hypertension and diabetes. Ann Hepatol. 2019;18(2):406-407.

[[12]] Yeap V, Tan TJY, Loh T, et al. Liver failure associated with mahogany seed extract consumption. BMJ Case Rep. 2018;2018:bcr2018225382.

[[13]] Vuppalanchi R, Bonkovsky HL, Ahmad J, et al. Garcinia cambogia, either alone or in combination with green tea, causes moderate to severe liver injury. Clin Gastroenterol Hepatol. 2022;20(6):e1416-e1425.

[[14]] Tan R, Hu Z, Zhou M, et al. Diosbulbin B: an important component responsible for hepatotoxicity and protein covalent binding induced by Dioscorea bulbifera L. Phytomedicine. 2022;102:154174.

[[15]] Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. Liver injury associated with turmeric-a growing problem: ten cases from the drug-induced liver injury network [DILIN]. Am J Med. 2023;136(2):200-206.

[[16]] Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. drug-induced liver injury network. Hepatology. 2014;60(4):1399-1408.

[[17]] Navarro VJ, Khan I, Bjornsson E, et al. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363-373.

[[18]] Ballotin VR, Bigarella LG, Brandão ABM, et al. Herb-induced liver injury: systematic review and meta-analysis. World J Clin Cases. 2021;9(20):5490-5513.

[[19]] Aiso M, Takikawa H, Tsuji K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol Res. 2019;49(1):105-110.

[[20]] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology. 2019;156(8):2230-2241.e11.

[[21]] Tu C, Niu M, Wei AW, et al. Susceptibility-related cytokine panel for prediction of polygonum multiflorum-induced hepatotoxicity in humans. J Inflamm Res. 2021;14:645-655.

[[22]] Gao Y, Wang ZL, Tang JF, et al. New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions. Front Med. 2020;14(1):68-80.

[[23]] Wang ZL, Xu G, Wang H, et al. Icariside II, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity by enhancing NLRP3 inflammasome activation. Acta Pharm Sin B. 2020;10(9):1619-1633.

[[24]] Melchart D.A joint statement for “tighter regulation” of traditional Chinese medicine issued by the federation of European academies of medicine (FEAM) and the European academies’ science advisory council (EASAC): scare stories or obstruction of access? Complement Med Res. 2020;27(1):3-5.

[[25]] Eigenschink M, Dearing L, Dablander TE, et al. A critical examination of the main premises of traditional Chinese medicine. Wien Klin Wochenschr. 2020;132(9-10):260-273.

[[26]] Wang Y, Qiao D, Li Y, et al. Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study. BMC Gastroenterol. 2018;18(1):156.

[[27]] Zhu L, Zhang CY, Li DP, et al. Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. Acta Pharmacol Sin. 2021;42(8):1212-1222.

[[28]] Wu L, Wang B, Zhao M, et al. Rapid identification of officinal Akebiae Caulis and its toxic adulterant Aristolochiae Manshuriensis Caulis (Aristolochia manshuriensis) by loop-mediated isothermal amplification. Front Plant Sci. 2016;7:887.

[[29]] Qiu Q, Liu ZH, Chen HP, et al. Long-term outcome of acute renal injury induced by Aristolochia manshuriensis Kom in rats. Acta Pharmacol Sin. 2000;21(12):1129-1135.

[[30]] Zhou Q, Pei J, Poon J, et al. Worldwide research trends on aristolochic acids (1957-2017): suggestions for researchers. PLoS One. 2019;14(5):e0216135.

[[31]] Yang B, Xie Y, Guo M, et al. Nephrotoxicity and Chinese herbal medicine. Clin J Am Soc Nephrol. 2018;13(10):1605-1611.

[[32]] Prozialeck WC, Edwards JR, Lamar PC, et al. Evaluation of the mitragynine content, levels of toxic metals and the presence of microbes in kratom products purchased in the western suburbs of Chicago. Int J Environ Res Public Health. 2020;17(15):5512.

[[33]] Li C, Su X, Feng WH, et al. Simultaneous determination of 12 mycotoxins in polygoni multiflori radix by UPLC-ESI-MS/MS combined with modified QuEChERS. Zhongguo Zhong Yao Za Zhi. 2016;41(23):4368-4374.

[[34]] Arroyo-Manzanares N, García-Campaña AM, Gámiz-Gracia L. Multiclass mycotoxin analysis in Silybum marianum by ultra high performance liquid chromatography-tandem mass spectrometry using a procedure based on QuEChERS and dispersive liquid-liquid microextraction. J Chromatogr A. 2013;1282:11-19.

[[35]] Han Z, Zheng Y, Luan L, et al. An ultra-high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of aflatoxins B1, B2, G1, G2, M1 and M2 in traditional Chinese medicines. Anal Chim Acta. 2010;664(2):165-171.

[[36]] Abdullah R, Diaz LN, Wesseling S, et al. Risk assessment of plant food supplements and other herbal products containing aristolochic acids using the margin of exposure (MOE) approach. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2017;34(2):135-144.

[[37]] Zhou Y, Huang W, Liu X, et al. Interannual variation and exposure risk assessment of lead in brick tea in Hubei, China. Sci Total Environ. 2020;745:141004.

[[38]] Hatami B, Saffaei A, Jamali F, et al. Glutamine powder-induced hepatotoxicity: it is time to understand the side effects of sports nutritional supplements. Gastroenterol Hepatol Bed Bench. 2020;13(1):86-89.

[[39]] Bastola S, Kc O, Khanal S, et al. Hepatitis-associated aplastic anemia from workout supplement: rare but potentially fatal entity. SAGE Open Med Case Rep.2020;8:2050313X20901937.

[[40]] Richards JR, Scheerlinck PH, Owen KP, et al. Bodybuilding supplements leading to copper toxicity, encephalopathy, fulminant hepatic failure and rhabdomyolysis. Am J Emerg Med. 2020;38(11):2487.e1-2487.e5.

[[41]] Villavicencio Kim J, Wu GY. Body building and aminotransferase elevations: a review. J Clin Transl Hepatol. 2020;8(2):161-167.

[[42]] Andueza N, Giner RM, Portillo MP. Risks associated with the use of Garcinia as a nutritional complement to lose weight. Nutrients. 2021;13(2):450.

[[43]] Bessone F, García-Cortés M, Medina-Caliz I, et al. Herbal and dietary supplements-induced liver injury in Latin America: experience from the LATINDILI network. Clin Gastroenterol Hepatol. 2022;20(3):e548-e563.

[[44]] Woo HJ, Kim HY, Choi ES, et al. Drug-induced liver injury: a 2-year retrospective study of 1169 hospitalized patients in a single medical center. Phytomedicine. 2015;22(13):1201-1205.

[[45]] Nadir A, Agrawal S, King PD, et al. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol. 1996;91(7):1436-1438.

[[46]] Neff GW, Reddy KR, Durazo FA, et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol. 2004;41(6):1062-1064.

[[47]] Kuchta K, Cameron S, Lee M, et al. Which East Asian herbal medicines can decrease viral infections? Phytochem Rev. 2022;21(1):219-237.

[[48]] Ma JX, Xiao X, Zhou KF, et al. Herb pair of Ephedrae Herba-Armeniacae Semen Amarum alleviates airway injury in asthmatic rats. J Ethnopharmacol. 2021;269:113745.

[[49]] Hoofnagle JH, Bonkovsky HL, Phillips EJ, et al. HLA-B*35:01 and green tea-induced liver injury. Hepatology. 2021;73(6):2484-2493.

[[50]] Hu J, Webster D, Cao J, et al. The safety of green tea and green tea extract consumption in adults—results of a systematic review. Regul Toxicol Pharmacol. 2018;95:412-433.

[[51]] Dekant W, Fujii K, Shibata E, et al. Safety assessment of green tea based beverages and dried green tea extracts as nutritional supplements. Toxicol Lett. 2017;277:104-108.

[[52]] Low EXS, Zheng Q, Chan E, et al. Drug induced liver injury: East versus West—a systematic review and meta-analysis. Clin Mol Hepatol. 2020;26(2):142-154.

[[53]] Gandhi D, Ahuja K, Quade A, et al. Kratom induced severe cholestatic liver injury histologically mimicking primary biliary cholangitis: a case report. World J Hepatol. 2020;12(10):863-869.

[[54]] Zheng E, Sandhu N, Navarro V. Drug-induced liver injury secondary to herbal and dietary supplements. Clin Liver Dis. 2020;24(1):141-155.

[[55]] Woo SM, Davis WD, Aggarwal S, et al. Herbal and dietary supplement induced liver injury: highlights from the recent literature. World J Hepatol. 2021;13(9):1019-1041.

[[56]] Lu H, Sheng R, Zhang C, et al. Comments regarding “Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature.”. Arch Toxicol. 2017;91(6):2493-2494.

[[57]] Kaur P, Shergill R, Mehta RG, et al. Biofunctional significance of multi-herbal combination against paracetamol-induced hepatotoxicity in Wistar rats. Environ Sci Pollut Res Int. 2021;28(43):61021-61046.

[[58]] Hoofnagle JH, Bjornsson ES. Drug-induced liver injury—types and phenotypes. N Engl J Med. 2019;381(3):264-273.

[[59]] Pan X, Zhou J, Chen Y, et al. Classification, hepatotoxic mechanisms, and targets of the risk ingredients in traditional Chinese medicine-induced liver injury. Toxicol Lett. 2020;323:48-56.

[[60]] Fontana RJ, Bjornsson ES, Reddy R, et al. The evolving profile of idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol. 2023;21(8):2088-2099.

[[61]] Allison R, Guraka A, Shawa IT, et al. Drug induced liver injury—a 2023 update. J Toxicol Environ Health B Crit Rev. 2023;26(8):442-467.

[[62]] Carpenter S, O’Neill LAJ. From periphery to center stage: 50 years of advancements in innate immunity. Cell. 2024;187(9):2030-2051.

[[63]] Wang JB, Song HB, Ge FL, et al. Landscape of DILI-related adverse drug reaction in China Mainland. Acta Pharm Sin B. 2022;12(12):4424-4431.

[[64]] Yu YC, Mao YM, Chen CW. Guidelines for the management of drug-induced liver injury. J Prac Hepatol. 2017;20(2):257-274.

[[65]] Lucena MI, Andrade RJ, Fernández MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44(4):850-856.

[[66]] Molleston JP, Fontana RJ, Lopez MJ, et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011;53(2):182-189.

[[67]] Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49(6):2001-2009.

[[68]] Wang JB, Zhu Y, Bai ZF, et al. Guidelines for the diagnosis and management of herb-induced liver injury. Chin J Integr Med. 2018;24(9):696-706.

[[69]] Wang JB, Li CY, Zhu Y, et al. Integrated evidence chain-based identification of Chinese herbal medicine-induced hepatotoxicity and rational usage: exemplification by Polygonum Multiflorum (He Shou Wu). Chin Sci Bull. 2016;61(9):971-980.

[[70]] Xiao XX, Tang JY, Mao YM, et al. Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injuryIssued by China food and drug administration. Acta Pharm Sin B. 2019;9(3):648-658.

[[71]] Philips CA, Theruvath AH, Ravindran R, et al. Complementary and alternative medicines and liver disease. Hepatol Commun. 2024;8(4):e0417.

[[72]] Guo ZJ, Li P, Wang CG, et al. Five constituents contributed to the Psoraleae Fructus-induced hepatotoxicity via mitochondrial dysfunction and apoptosis. Front Pharmacol. 2021;12:682823.

[[73]] Tu C, He Q, Li CY, et al. Susceptibility-related factor and biomarkers of dietary supplement Polygonum multiflorum-induced liver injury in rats. Front Pharmacol. 2019;10:335.

[[74]] Zhang ML, Zhao X, Li WX, et al. Yin/Yang associated differential responses to Psoralea corylifolia Linn. In rat models: an integrated metabolomics and transcriptomics study. Chin Med. 2023;18(1):102.

[[75]] Rao T, Liu YT, Zeng XC, et al. The hepatotoxicity of Polygonum multiflorum: the emerging role of the immune-mediated liver injury. Acta Pharmacol Sin. 2021;42(1):27-35.

[[76]] Tu C, Jiang BQ, Zhao YL, et al. Comparison of processed and crude Polygoni Multiflori radix induced rat liver injury and screening for sensitive indicators. Zhongguo Zhong Yao Za Zhi. 2015;40(4):654-660.

[[77]] Wang J, Ma Z, Niu M, et al. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum. Front Med. 2015;9(4):457-467.

[[78]] Zhang L, Niu M, Wei AW, et al. Clinical correlation between serum cytokines and the susceptibility to Polygonum multiflorum-induced liver injury and an experimental study. Food Funct. 2022;13(2):825-833.

[[79]] Zhang L, Niu M, Wei AW, et al. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum. Arch Toxicol. 2020;94(1):245-256.

[[80]] Wang JB, Cui HR, Bai ZF, et al. Precision medicine-oriented safety assessment strategy for traditional Chinese medicines: disease-syndrome-based toxicology. Yao Xue Xue Bao. 2016;51(11):1681-1688.

[[81]] Tu C, Ge FL, Guo YM, et al. Analysis of clinical characteristics and medication rationality of Polygonum Multiflorum Thunb. and its preparation-related liver injury. Chin J Pharmacov. 2019;16(5):270-276.

[[82]] Guo YM, Tu C, He Q, et al. Safety administration strategy for Heshouwu (Polygoni Multiflori Radix) based on properties and actions of Chinese medicine. J Tradit Chin Med. 2018;59(9):721-724.

[[83]] Li C, Rao T, Chen X, et al. HLA-B*35:01 allele is a potential biomarker for predicting Polygonum multiflorum-induced liver injury in humans. Hepatology. 2019;70(1):346-357.

[[84]] Aithal GP. Of potions, poisons, Polygonum, and pre-emptive polymorphism. Hepatology. 2019;70(1):8-10.

[[85]] Zhang L, Liu X, Tu C, et al. Components synergy between stilbenes and emodin derivatives contributes to hepatotoxicity induced by Polygonum multiflorum. Xenobiotica. 2019;50(5):515-525.

[[86]] Li C, Niu M, Bai Z, et al. Screening for main components associated with the idiosyncratic hepatotoxicity of a tonic herb, Polygonum multiflorum. Front Med. 2017;11(2):253-265.

[[87]] He L, Yin P, Meng Y, et al. Immunological synergistic mechanisms of trans-/cis-stilbene glycosides in Heshouwu-related idiosyncratic liver injury. Science Bulletin. 2017;62(11):748-751.

[[88]] Qin N, Xu G, Wang Y, et al. Bavachin enhances NLRP3 inflammasome activation induced by ATP or nigericin and causes idiosyncratic hepatotoxicity. Front Med. 2021;15(4):594-607.

[[89]] Gao Y, Xu G, Ma L, et al. Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Cell Commun Signal. 2021;19(1):13.

[[90]] Wang Z, Xu G, Zhan X, et al. Carbamazepine promotes specific stimuli-induced NLRP3 inflammasome activation and causes idiosyncratic liver injury in mice. Arch Toxicol. 2019;93(12):3585-3599.

[[91]] Wang Z, Xu G, Gao Y, et al. Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome. Acta Pharm Sin B. 2019;9(4):734-744.

[[92]] BCPM CACM, BHD CACM, CCCP CPA, . Guidelines for safe use of Polygoni Multiflori radix. Zhongguo Zhong Yao Za Zhi. 2020;45(5):961-966.

[[93]] Song D, Chen SS, Li PY, et al. Attenuating the potential hepatotoxicity of Psoraleae Fructus by pre-processing: the alcohol soaking and water rinsing method. Yao Xue Xue Bao. 2020;55(2):276-282.

[[94]] Gao D, Pang JY, Zhang CE, et al. Poria attenuates idiosyncratic liver injury induced by Polygoni Multiflori radix praeparata. Front Pharmacol. 2016;7:386.

[[95]] Han T, Xu W, Wang X, et al. Emodin-8-O-β-D-glucopyranoside-induced hepatotoxicity and gender differences in zebrafish as revealed by integration of metabolomics and transcriptomics. Phytomedicine. 2024;128:155411.

[[96]] Gao D, Li XF, Yin P, et al. Preliminary study on hepatotoxic components in Polygoni Multiflori radix based on processing and toxicity-decreasing. Chin Tradi Herb Drugs. 2017;48(10):2044-2050.

[[97]] Li RY, Feng WW, Li XF, et al. Influence of metal ions on stability of 2,3,5,4’-tetrahydroxy stilbene-2-O-β-D-glucoside contained in Polygoni Multiflori radix. Yao Xue Xue Bao. 2016;51(1):116-121.

RIGHTS & PERMISSIONS

2024 Acupuncture and Herbal Medicine